Subcutaneous Drug Delivery Devices Market Size, Share & Trends Analysis Report By Product (Prefilled Syringes, Pen Injectors, Wearable Injectors), By Distribution Channel, By Region, And Segment Forecasts, 2020 - 2027

Report Overview

The global subcutaneous drug delivery devices market size was valued at USD 21.2 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 10.4% from 2020 to 2027. Availability of advanced minimally invasive drug delivery devices, rising prevalence of diabetes and Cardiovascular Diseases (CVD), and a surge in biologic drug development have driven the demand for subcutaneous self-administrating drug delivery devices. According to the International Diabetes Federation (IDF), the diabetic population is anticipated to grow by 48.0% annually between 2017 and 2045 globally. IDF further stated that diabetes incidence will majorly rise drastically in low and middle-income countries, as compared to the developed countries. Also, as per the World Heart Federation, adults with type 2 diabetes are highly susceptible to develop CVD, as compared to non-diabetics.

Increasing adoption of subcutaneous drug delivery devices has resulted in the reduction in dosage errors and the prevention of needlestick injuries. Higher treatment adherence is observed in patients with devices having easy drug administration protocols. According to the Annals of Internal Medicine, nearly 50.0% of patients with prescriptions for chronic conditions stop taking it within the first year. Moreover, the study also stated that lack of treatment adherence leads to 125,000 deaths, 10.0% hospitalizations, and costs USD 17 billion to the American healthcare system annually. Thus, pain-free subcutaneous drug delivery devices can directly have an impact on managing several chronic medical conditions.

The needle-free injectors have emerged as potential alternatives for conventional drug delivery platforms as they eliminate needlestick injuries and reduce associated treatment costs.  According to the Occupational Safety and Health Administration, 384,000 needlestick injuries and other sharps-related injuries are reported in the healthcare personnel in the U.S. annually. According to the survey conducted by PATH Vaccine Resource Library, 21.0 million hepatitis B, 260,000 HIV, and 2 million hepatitis C infections are registered from needlestick injuries, leading to 1.3 million early deaths globally.

Product Insights

The pen injectors segment dominated the market for subcutaneous drug delivery devices and accounted for the largest revenue share of 38.0% in 2019. Increasing product approvals, easy product design, affordability, and greater social acceptance are positive growth indicators. The developers are engaged in addressing the shortcomings of these delivery devices to gain a competitive edge in the market for subcutaneous drug delivery devices. For instance, in March 2018, Sanofi S.A. announced the U.S. FDA approval for its maximum unit injection pen - Toujeo Max SoloStar. The device is designed to accommodate a volume of 900 units/mL. The device will help in reducing injection numbers and thus lower medical spending.

The wearable injectors segment is expected to register the highest growth rate in the subcutaneous drug delivery devices market over the forecast period. The wearable injectors, also called patch pumps or bolus injectors are increasingly prescribed by physicians to administer high-viscosity and large-volume biologic drugs. These digitally powered subcutaneous drug delivery devices can help the physicians to improve the quality of care, thereby reducing total healthcare costs by improving patient outcomes.

Distribution Channel Insights

The retail pharmacies segment accounted for the largest revenue share of 44.9% in 2019 in the market for subcutaneous drug delivery devices. This can be attributable to factors such as increasing self-administration, patient awareness, and increasing focus on positive medical outcomes. Also, manufacturers are launching programs to enable uninterrupted access to insulin for uninsured patients, thus helping patients amid the COVID crisis.

The online pharmacies segment is expected to showcase the fastest growth rate due to discounts offered by the developers for various subcutaneous drug delivery devices. For instance, in 2017, Eli Lilly partnered with Express Scripts to offer discounts for their products for mobile and web platforms. Thus, the cost-effectiveness of vital medications enables greater access to patients in underdeveloped and developing countries.

Regional Insights

North America dominated the market for subcutaneous drug delivery devices and accounted for the largest revenue share of 44.1% in 2019. The region is expected to continue its dominance over the forecast period. This dominance is attributed to developed healthcare infrastructure, local presence of major players, and continuous strategic initiatives implemented to maintain their market share. In December 2019, Portal Instruments, Inc. collaborated with LEO Pharma for the development of a needle-free subcutaneous drug delivery device. Moreover, the increasing prevalence of chronic disease conditions such as multiple sclerosis, cardiovascular diseases, diabetes, and arthritis contribute majorly to the growth of the market for subcutaneous drug delivery devices. According to the National Multiple Sclerosis Society, an estimated 1.0 million adults were reported to be living with multiple sclerosis in the U.S. in 2017.

In Asia Pacific, the market for subcutaneous drug delivery devices is expected to grow at a lucrative rate over the forecast period. The high growth rate in the region is primarily attributed to the rise in diabetic patients. According to the International Diabetes Federation (IDF), Asia comprises 60.0% of the global diabetic population. IDF further stated that India is predicted to have the highest growth rate in terms of diabetics by 2025, with 72.0 million cases recorded in 2017.

Key Companies & Market Share Insights

The market for subcutaneous drug delivery devices is highly fragmented with the presence of various large and medium-scale vendors offering a variety of subcutaneous drug delivery devices indicated for different disease conditions. Product launch, strategic acquisitions, and product innovation are the major strategies adopted by the market players to retain their market share. In June 2018, Insulet Corporation received the U.S. FDA approval for the Omnipod DASH insulin management system. These digital platforms enable better patient outcomes in diabetic patients. Some of the prominent players in the subcutaneous drug delivery devices market include:

• Gerresheimer AG

• Medtronic Plc

• Ypsomed AG

• Elcam Medical Group

• Novo Nordisk

• Insulet Corporation

• Becton, Dickinson and Company

• West Pharmaceutical Services, Inc.

• PharmaJet

• Unilife Corporation

• Inolife Sciences       

Subcutaneous Drug Delivery Devices Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global subcutaneous drug delivery devices market report based on product, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2016 - 2027)

  • Prefilled syringes

  • Pen injectors

  • Auto-injectors

  • Wearable injectors

  • Needle-free Injectors

• Distribution Channel Outlook (Revenue, USD Million, 2016 - 2027)

  • Hospital pharmacies

  • Retail pharmacies

  • Online pharmacies

• Regional Outlook (Revenue, USD Million, 2016 - 2027) 

  • North America

    • The U.S.

    • Canada

  • Europe

    • The U.K

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE